Your browser doesn't support javascript.
loading
Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.
Orlowski, Robert Z; Nagler, Arnon; Sonneveld, Pieter; Bladé, Joan; Hajek, Roman; Spencer, Andrew; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J; Suvorov, Alexander N; Xiu, Liang; Cakana, Andrew; Parekh, Trilok; San-Miguel, Jesús F.
Afiliação
  • Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
  • Nagler A; Division of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
  • Sonneveld P; Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • Bladé J; Department of Clinical Hematology, August Pi I Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.
  • Hajek R; Department of Hemato-Oncology, University Hospital and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Spencer A; Malignant Hematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia.
  • Robak T; Department of Hematology, Medical University of Lódz, Lódz, Poland.
  • Dmoszynska A; Hematology and Bone Marrow Transplant Department, Medical University of Lublin, Lublin, Poland.
  • Horvath N; Department of Hematology, Royal Adelaide Hospital, West Australia, Australia.
  • Spicka I; Department of Internal Medicine, Charles University General Faculty Hospital, Prague, Czech Republic.
  • Sutherland HJ; Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Suvorov AN; Department of Hematology, First Republican Clinical Hospital of the Ministry of Healthcare of the Udmurt Republic, Izhevsk, Russia.
  • Xiu L; Janssen Research & Development, LLC, Raritan, New Jersey.
  • Cakana A; Janssen Research & Development, LLC, Raritan, New Jersey.
  • Parekh T; Janssen Research & Development, LLC, Raritan, New Jersey.
  • San-Miguel JF; Center for Applied Medical Research, August Pi I Sunyer Biomedical Research Institute, University of Navarra, Pamplona, Spain.
Cancer ; 122(13): 2050-6, 2016 Jul 01.
Article em En | MEDLINE | ID: mdl-27191689
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Bortezomib / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Doxorrubicina / Bortezomib / Mieloma Múltiplo / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Guideline Limite: Female / Humans / Male Idioma: En Ano de publicação: 2016 Tipo de documento: Article